Compare Stocks: EIKN, SLS, BHVN, and STOK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$14.66 -1.3%	$14.24	$7.48 ▼ $18.57	$2.22B	1.26	2.56 million shs	596,744 shs
EIKN Eikon Therapeutics	$10.97 +6.2%	$10.03	$7.90 ▼ $17.40	$593.37M	N/A	368,714 shs	359,527 shs
SLS SELLAS Life Sciences Group	$12.63 +2.2%	$11.15	$1.39 ▼ $15.88	$2.55B	2.48	8.24 million shs	2.84 million shs
STOK Stoke Therapeutics	$31.02 -0.9%	$30.67	$16.90 ▼ $40.22	$2.00B	1.2	751,963 shs	314,713 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+3.51%	+3.59%	-0.70%	+70.14%	+3.23%
EIKN Eikon Therapeutics	-0.86%	+12.16%	+1.37%	-22.04%	+1,032,999,900.00%
SLS SELLAS Life Sciences Group	+5.01%	+5.64%	-7.69%	+74.58%	+700.00%
STOK Stoke Therapeutics	-5.03%	-1.94%	+7.48%	+4.09%	+85.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$14.66 -1.3%	$14.24	$7.48 ▼ $18.57	$2.22B	1.26	2.56 million shs	596,744 shs
EIKN Eikon Therapeutics	$10.97 +6.2%	$10.03	$7.90 ▼ $17.40	$593.37M	N/A	368,714 shs	359,527 shs
SLS SELLAS Life Sciences Group	$12.63 +2.2%	$11.15	$1.39 ▼ $15.88	$2.55B	2.48	8.24 million shs	2.84 million shs
STOK Stoke Therapeutics	$31.02 -0.9%	$30.67	$16.90 ▼ $40.22	$2.00B	1.2	751,963 shs	314,713 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+3.51%	+3.59%	-0.70%	+70.14%	+3.23%
EIKN Eikon Therapeutics	-0.86%	+12.16%	+1.37%	-22.04%	+1,032,999,900.00%
SLS SELLAS Life Sciences Group	+5.01%	+5.64%	-7.69%	+74.58%	+700.00%
STOK Stoke Therapeutics	-5.03%	-1.94%	+7.48%	+4.09%	+85.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.65	Moderate Buy	$21.75	50.82% Upside
EIKN Eikon Therapeutics	2.38	Hold	$25.00	125.57% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-19.81% Downside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	39.97% Upside

Current Analyst Ratings Breakdown

Latest EIKN, SLS, BHVN, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/4/2026	STOK Stoke Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/4/2026	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$38.00 ➝ $40.00
8/4/2026	STOK Stoke Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $58.00
8/4/2026	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/17/2026	SLS SELLAS Life Sciences Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A
STOK Stoke Therapeutics	$184.42M	10.75	N/A	N/A	$5.36 per share	5.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,070.80%	-132.67%	N/A
EIKN Eikon Therapeutics	-$324.25M	-$2.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	-$26.86M	-$0.23	N/A	N/A	N/A	N/A	-43.49%	-39.90%	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	N/A

Latest EIKN, SLS, BHVN, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	1.87	7.41	7.41
EIKN Eikon Therapeutics	N/A	11.75	11.75
SLS SELLAS Life Sciences Group	N/A	17.22	17.22
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
EIKN Eikon Therapeutics	N/A
SLS SELLAS Life Sciences Group	17.38%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
EIKN Eikon Therapeutics	N/A
SLS SELLAS Life Sciences Group	1.30%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	151.04 million	129.78 million	Optionable
EIKN Eikon Therapeutics	384	54.14 million	N/A	N/A
SLS SELLAS Life Sciences Group	10	201.95 million	194.08 million	Not Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable

EIKN, SLS, BHVN, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

August 11 at 7:49 AM | finance.yahoo.com

The Manufacturers Life Insurance Company Purchases 55,672 Shares of Stoke Therapeutics, Inc. $STOK

August 9, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A.

August 9, 2026 | marketbeat.com

Research Analysts Offer Predictions for STOK Q3 Earnings

August 8, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

HC Wainwright Has Bearish Forecast for STOK FY2029 Earnings

August 7, 2026 | americanbankingnews.com

Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright

August 6, 2026 | marketbeat.com

Barry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

August 6, 2026 | insidertrades.com

Wedbush Increases Stoke Therapeutics (NASDAQ:STOK) Price Target to $40.00

August 6, 2026 | americanbankingnews.com

Canaccord Genuity Group Issues Pessimistic Forecast for Stoke Therapeutics (NASDAQ:STOK) Stock Price

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

August 5, 2026 | marketbeat.com

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

August 5, 2026 | seekingalpha.com

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026 | finance.yahoo.com

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

August 5, 2026 | theglobeandmail.com

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

August 5, 2026 | finance.yahoo.com

FY2029 Earnings Estimate for STOK Issued By HC Wainwright

August 5, 2026 | marketbeat.com

Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK

August 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Guggenheim

August 4, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings

August 4, 2026 | 247wallst.com

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

August 4, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SLS, BHVN, and STOK Company Descriptions

Biohaven NYSE:BHVN

$14.66 -0.19 (-1.28%)

As of 03:05 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Eikon Therapeutics NASDAQ:EIKN

$10.97 +0.64 (+6.20%)

As of 03:05 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

SELLAS Life Sciences Group NASDAQ:SLS

$12.63 +0.27 (+2.18%)

As of 03:05 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Stoke Therapeutics NASDAQ:STOK

$31.02 -0.29 (-0.93%)

As of 03:05 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SLS, BHVN, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SLS, BHVN, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SLS, BHVN, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SLS, BHVN, and STOK Company Descriptions

Biohaven NYSE:BHVN

Eikon Therapeutics NASDAQ:EIKN

SELLAS Life Sciences Group NASDAQ:SLS

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EIKN, SLS, BHVN, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EIKN, SLS, BHVN, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EIKN, SLS, BHVN, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN, SLS, BHVN, and STOK Company Descriptions

Biohaven NYSE:BHVN

Eikon Therapeutics NASDAQ:EIKN

SELLAS Life Sciences Group NASDAQ:SLS

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools